Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune Inc
(NQ:
ALT
)
6.550
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Altimmune Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via
InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
April 09, 2024
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Via
The Motley Fool
How Is The Market Feeling About Altimmune?
April 08, 2024
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
April 03, 2024
Via
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
March 28, 2024
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat...
Via
Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
March 27, 2024
ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Altimmune's Earnings Outlook
March 26, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
March 22, 2024
Via
Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 28, 2024
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of...
Via
Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
March 28, 2024
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break.
Via
Investor's Business Daily
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
March 18, 2024
Via
Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
February 28, 2024
Via
Benzinga
(ALT) - Analyzing Altimmune's Short Interest
February 14, 2024
Via
Benzinga
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
March 27, 2024
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Earnings Scheduled For March 27, 2024
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
March 19, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.
Via
Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
March 15, 2024
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
Via
The Motley Fool
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
March 01, 2024
The Nasdaq is on the cusp of setting a record high.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Stocks Start Week On A Hesitant Note
February 26, 2024
Stocks are barely moving to start the week, just one session removed from record highs.
Via
Talk Markets
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.
Via
Investor's Business Daily
Altimmune Stock Surges, Kerrisdale Remains Short: What You Need To Know
February 26, 2024
Altimmune shares are trading higher Monday despite a lack of company-specific news. Kerrisdale Capital told Benzinga on Monday that the firm is still short Altimmune stock.
Via
Benzinga
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Exposures
Product Safety
Why Is Altimmune (ALT) Stock Up 14% Today?
February 26, 2024
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 26, 2024
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.